5GV Stock Overview
Develops and sells tools for the development of new treatment methods and diagnostics for customers in the pharmaceutical and research industries. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Genovis AB (publ.) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 1.79 |
| 52 Week High | SEK 3.42 |
| 52 Week Low | SEK 1.61 |
| Beta | 1.69 |
| 1 Month Change | -23.91% |
| 3 Month Change | -16.45% |
| 1 Year Change | -34.51% |
| 3 Year Change | -66.01% |
| 5 Year Change | 13.52% |
| Change since IPO | 345.89% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5GV | DE Life Sciences | DE Market | |
|---|---|---|---|
| 7D | -13.4% | -1.6% | -0.5% |
| 1Y | -34.5% | -15.7% | 15.5% |
Return vs Industry: 5GV underperformed the German Life Sciences industry which returned -17.3% over the past year.
Return vs Market: 5GV underperformed the German Market which returned 13.6% over the past year.
Price Volatility
| 5GV volatility | |
|---|---|
| 5GV Average Weekly Movement | 6.8% |
| Life Sciences Industry Average Movement | 7.1% |
| Market Average Movement | 5.3% |
| 10% most volatile stocks in DE Market | 11.9% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: 5GV has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: 5GV's weekly volatility (7%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1999 | 32 | Fredrik Olsson | www.genovis.com |
Genovis AB (publ.) develops and sells tools for the development of new treatment methods and diagnostics for customers in the pharmaceutical and research industries. The company provides FabALACTICA, a cysteine protease; FabRICATOR, a cysteine protease; and FabRICATOR Z, for the digestion of mouse IgG2a and IgG3, and generating a homogenous pool of F(ab')2 and Fc fragments. It offers FabULOUS (SpeB), a cysteine protease; GingisKHAN, a cysteine protease; FabDELLO, a protease that digests human IgG1; IgASAP, an IgA-digesting enzyme; and IgMBRAZOR, an IgM-specific protease.
Genovis AB (publ.) Fundamentals Summary
| 5GV fundamental statistics | |
|---|---|
| Market cap | €129.48m |
| Earnings (TTM) | €2.99m |
| Revenue (TTM) | €13.25m |
43.4x
P/E Ratio9.8x
P/S RatioIs 5GV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5GV income statement (TTM) | |
|---|---|
| Revenue | SEK 146.00m |
| Cost of Revenue | SEK 16.10m |
| Gross Profit | SEK 129.90m |
| Other Expenses | SEK 96.98m |
| Earnings | SEK 32.92m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
Apr 28, 2025
| Earnings per share (EPS) | 0.50 |
| Gross Margin | 88.97% |
| Net Profit Margin | 22.55% |
| Debt/Equity Ratio | 0% |
How did 5GV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/14 11:56 |
| End of Day Share Price | 2025/03/14 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Genovis AB (publ.) is covered by 4 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Daniel Albin | Danske Bank |
| Simon Larsson | Danske Bank |
| Ludvig Lundgren | Nordea Markets |